PMC:7544934 / 30140-30593 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T87","span":{"begin":282,"end":285},"obj":"https://glytoucan.org/Structures/Glycans/G00057MO"},{"id":"T88","span":{"begin":282,"end":285},"obj":"https://glytoucan.org/Structures/Glycans/G31736BK"}],"text":"Our data provide a proof-of-concept for the potential feasibility of repurposing of FDA approved non-peptide opioid antagonist; naltrexone as host-targeted broad-spectrum antiviral therapies to combat COVID-19 infections. The next step will be to confirm data in COVID-19 patients. LDN alone or as an adjuvant therapy with hydroxychloroquine or an antiviral agent may give physicians more time to provide supportive treatment for patients with COVID-19."}

{"project":"LitCovid-PubTator","denotations":[{"id":"725","span":{"begin":272,"end":280},"obj":"Species"},{"id":"726","span":{"begin":430,"end":438},"obj":"Species"},{"id":"727","span":{"begin":128,"end":138},"obj":"Chemical"},{"id":"728","span":{"begin":282,"end":285},"obj":"Chemical"},{"id":"729","span":{"begin":323,"end":341},"obj":"Chemical"},{"id":"730","span":{"begin":201,"end":209},"obj":"Disease"},{"id":"731","span":{"begin":210,"end":220},"obj":"Disease"},{"id":"732","span":{"begin":263,"end":271},"obj":"Disease"},{"id":"733","span":{"begin":444,"end":452},"obj":"Disease"}],"attributes":[{"id":"A725","pred":"tao:has_database_id","subj":"725","obj":"Tax:9606"},{"id":"A726","pred":"tao:has_database_id","subj":"726","obj":"Tax:9606"},{"id":"A727","pred":"tao:has_database_id","subj":"727","obj":"MESH:D009271"},{"id":"A729","pred":"tao:has_database_id","subj":"729","obj":"MESH:D006886"},{"id":"A730","pred":"tao:has_database_id","subj":"730","obj":"MESH:C000657245"},{"id":"A731","pred":"tao:has_database_id","subj":"731","obj":"MESH:D007239"},{"id":"A732","pred":"tao:has_database_id","subj":"732","obj":"MESH:C000657245"},{"id":"A733","pred":"tao:has_database_id","subj":"733","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Our data provide a proof-of-concept for the potential feasibility of repurposing of FDA approved non-peptide opioid antagonist; naltrexone as host-targeted broad-spectrum antiviral therapies to combat COVID-19 infections. The next step will be to confirm data in COVID-19 patients. LDN alone or as an adjuvant therapy with hydroxychloroquine or an antiviral agent may give physicians more time to provide supportive treatment for patients with COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T207","span":{"begin":0,"end":221},"obj":"Sentence"},{"id":"T208","span":{"begin":222,"end":281},"obj":"Sentence"},{"id":"T209","span":{"begin":282,"end":453},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Our data provide a proof-of-concept for the potential feasibility of repurposing of FDA approved non-peptide opioid antagonist; naltrexone as host-targeted broad-spectrum antiviral therapies to combat COVID-19 infections. The next step will be to confirm data in COVID-19 patients. LDN alone or as an adjuvant therapy with hydroxychloroquine or an antiviral agent may give physicians more time to provide supportive treatment for patients with COVID-19."}